Stay updated on Sitravatinib and Tislelizumab in Uveal Melanoma Clinical Trial

Sign up to get notified when there's something new on the Sitravatinib and Tislelizumab in Uveal Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Sitravatinib and Tislelizumab in Uveal Melanoma Clinical Trial page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    Change Detected
    Summary
    Added Revision: v3.4.2 and removed the previous notices (funding lapse notice and Revision: v3.4.1). This is an administrative update and does not affect the trial information or how users interact with the page.
    Difference
    0.4%
    Check dated 2026-02-11T02:07:58.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    Added a site-wide notice about a lapse in government funding and the NIH Clinical Center's operating status, including guidance that information may not be up to date. Also updated the site version to Revision: v3.4.1 and removed the previous Revision: v3.4.0 tag.
    Difference
    0.4%
    Check dated 2026-02-03T23:48:19.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    UI/metadata updates (glossary toggle, 'Last Update Submitted that Met QC Criteria' label, and footer changes 'No FEAR Act Data' and 'Revision: v3.4.0') do not affect core study content, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2026-01-27T17:46:04.000Z thumbnail image
  5. Check
    35 days ago
    Change Detected
    Summary
    Revision: v3.3.4 replaces v3.3.3 on the site, with no observable changes to the study details page or its core content. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-20T14:16:25.000Z thumbnail image
  6. Check
    64 days ago
    Change Detected
    Summary
    Added study locations (Andalusia, Barcelona, Madrid, Valencia) and updated the page revision to v3.3.3. Removed the HHS Vulnerability Disclosure section and its v3.3.2 reference.
    Difference
    0.6%
    Check dated 2025-12-22T22:31:34.000Z thumbnail image
  7. Check
    85 days ago
    Change Detected
    Summary
    Revision updated from v3.3.1 to v3.3.2 on the page, indicating a minor version change. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-12-01T15:41:39.000Z thumbnail image

Stay in the know with updates to Sitravatinib and Tislelizumab in Uveal Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Sitravatinib and Tislelizumab in Uveal Melanoma Clinical Trial page.